Chevy Chase Trust Holdings Inc. decreased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 0.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,437,691 shares of the biopharmaceutical company’s stock after selling 4,093 shares during the quarter. Chevy Chase Trust Holdings Inc.’s holdings in Bristol-Myers Squibb were worth $79,562,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in Bristol-Myers Squibb during the 1st quarter valued at approximately $101,000. Institutional & Family Asset Management LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter valued at approximately $106,000. Centerpoint Advisors LLC boosted its position in Bristol-Myers Squibb by 373.1% during the 1st quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 1,399 shares during the period. Mount Yale Investment Advisors LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter valued at approximately $179,000. Finally, Valmark Advisers Inc. acquired a new position in Bristol-Myers Squibb during the 1st quarter valued at approximately $202,000. Institutional investors own 71.39% of the company’s stock.
Shares of Bristol-Myers Squibb opened at $59.53 on Friday, MarketBeat.com reports. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46. Bristol-Myers Squibb Co has a 1 year low of $49.96 and a 1 year high of $70.05. The firm has a market cap of $96.41 billion, a price-to-earnings ratio of 17.45, a price-to-earnings-growth ratio of 1.49 and a beta of 1.02.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 1st. Stockholders of record on Friday, July 6th were paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date was Thursday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.
A number of research analysts recently issued reports on BMY shares. Credit Suisse Group set a $58.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Tuesday, April 17th. BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $51.00 to $47.00 and set an “underperform” rating for the company in a research report on Wednesday, April 18th. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, April 17th. UBS Group lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and set a $57.00 price objective for the company. in a research report on Monday, May 21st. Finally, ValuEngine lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $63.11.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: Growth Stocks
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.